Document Detail


Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.
MedLine Citation:
PMID:  23406976     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Mechanisms for increased cardiovascular risk in HIV-1-infected adults are incompletely understood, but platelet activation and immune activation leading to a prothrombotic state have been proposed as significant contributors. Aspirin has antiplatelet and immunomodulatory properties. We explored whether 1 week of low-dose aspirin attenuates platelet activation and immune activation in HIV-1-infected and virologically suppressed adults on antiretroviral therapy.
METHODS: Platelet activation and immune activation were measured in HIV-1-infected subjects virologically suppressed on antiretroviral therapy and controls before and after 1 week of low-dose aspirin.
RESULTS: Compared with control subjects, HIV-1-infected subjects had increased platelet activation, as measured by spontaneous platelet aggregation and aggregation in response to adenosine diphosphate, collagen, and arachidonic acid. After aspirin therapy, percent aggregation decreased similarly in both HIV-1-infected and control subjects to all platelet agonists tested except aggregation in response to arachidonic acid, which remained elevated in the HIV-1-infected group. HIV-1-infected subjects exhibited increased markers of T-cell activation (CD38 and HLA-DR) and monocyte activation (sCD14), which decreased after 1 week of aspirin therapy. Moreover, leukocyte responses to Toll-like receptor stimulation were enhanced after 1 week of aspirin therapy. In vitro studies showed that HIV-1 plasma could activate healthy platelets, which in turn activated monocytes, implicating a direct role for activated platelets in immune activation.
CONCLUSIONS: Our data demonstrate that heightened platelet activation and immune activation in treated HIV-1 disease are attenuated by 1 week of aspirin therapy. Aspirin should be further studied for its antithrombotic and immunomodulatory benefits in treated HIV-1 disease.
Authors:
Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger
Related Documents :
23715106 - Heparin-induced thrombocytopenia associated with thrombotic microangiopathy.
23272296 - Acidosis and correction of acidosis does not affect rfviia function in swine.
3341066 - Evaluation of a centrifugal blood cell processor for washing platelet concentrates.
4002306 - Kinetics and mobilization from the spleen of indium-111-labeled platelets during platel...
24219176 - Inhibitory effects of kiwifruit extract on human platelet aggregation and plasma angiot...
9882436 - Protein disulfide isomerase catalyzes the formation of disulfide-linked complexes of th...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  63     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2013-08-29     Revised Date:  2014-07-02    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  280-8     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Diphosphate / pharmacology
Adult
Aged
Anti-HIV Agents / therapeutic use
Arachidonic Acid / pharmacology
Aspirin / pharmacology,  therapeutic use*
Cells, Cultured
Collagen / pharmacology
Female
HIV Infections / blood*,  drug therapy,  immunology*
HIV-1* / drug effects
Humans
Inflammation / drug therapy
Lymphocyte Activation / drug effects*
Male
Middle Aged
P-Selectin / blood
Pilot Projects
Platelet Activation / drug effects*
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors / pharmacology,  therapeutic use
Platelet Function Tests
Thromboxanes / urine
Young Adult
Grant Support
ID/Acronym/Agency:
5 U01 AI069532/AI/NIAID NIH HHS; K08 AI093153/AI/NIAID NIH HHS; P30 AI027742/AI/NIAID NIH HHS; UL1 TR000038/TR/NCATS NIH HHS; UM1 AI069532/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/P-Selectin; 0/Platelet Aggregation Inhibitors; 0/Thromboxanes; 27YG812J1I/Arachidonic Acid; 61D2G4IYVH/Adenosine Diphosphate; 9007-34-5/Collagen; R16CO5Y76E/Aspirin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The clinical significance of calcium-signalling pathways mediating human sperm hyperactivation.
Next Document:  Evaluation of using Routine Infant Immunization Visits to Identify and Follow-up HIV-exposed Infants...